Merus (NASDAQ:MRUS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday.
According to Zacks, “Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company’s bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands. “
A number of other analysts also recently weighed in on the company. Wedbush restated an “outperform” rating and issued a $32.00 price target (up from $26.00) on shares of Merus in a research note on Monday, April 30th. BidaskClub upgraded Merus from a “sell” rating to a “hold” rating in a research note on Friday, April 27th. Finally, ValuEngine upgraded Merus from a “strong sell” rating to a “sell” rating in a research note on Monday, April 2nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. Merus currently has an average rating of “Hold” and a consensus target price of $27.50.
Shares of MRUS stock opened at $17.90 on Wednesday. Merus has a twelve month low of $13.23 and a twelve month high of $22.46. The company has a market capitalization of $392.31 million, a price-to-earnings ratio of -4.17 and a beta of 0.15.
Several institutional investors have recently bought and sold shares of MRUS. BVF Inc. IL purchased a new stake in shares of Merus in the first quarter valued at approximately $44,832,000. Bain Capital Public Equity Management LLC purchased a new stake in shares of Merus in the fourth quarter valued at approximately $8,297,000. Stanley Laman Group Ltd. purchased a new stake in shares of Merus in the first quarter valued at approximately $860,000. Finally, Deutsche Bank AG boosted its stake in shares of Merus by 146.6% in the fourth quarter. Deutsche Bank AG now owns 9,400 shares of the biotechnology company’s stock valued at $182,000 after buying an additional 5,588 shares in the last quarter. Hedge funds and other institutional investors own 26.62% of the company’s stock.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers.
Get a free copy of the Zacks research report on Merus (MRUS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.